{
    "clinical_study": {
        "@rank": "72202", 
        "arm_group": [
            {
                "arm_group_label": "Outer-Root-Sheath Melanocytes Suspension", 
                "arm_group_type": "Experimental", 
                "description": "This arm includes all patients sides (left or right) treated with autologous outer-root-sheath melanocytes suspension"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "This arm includes all patients sides (left or right) treated with placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the hypothesis that, in patients with stable\n      vitiligo unresponsive to conventional treatments including traditional phototherapy and/or\n      topical steroids, the application of a non-cultured autologous hair follicle\n      outer-root-sheath melanocytes suspension in the area affected by the disease can lead to a\n      significant skin repigmentation. To preliminarily assess the effect of the proposed\n      treatment, a pilot within-subject controlled study involving symmetric lesions localized to\n      the back of the hands will be conducted."
        }, 
        "brief_title": "Efficacy of Autologous Outer-Root-Sheath Melanocytes Transplantation in the Treatment of Vitiligo", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Vitiligo", 
        "condition_browse": {
            "mesh_term": "Vitiligo"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Presence of symmetric lesions of vitiligo at the back of the hands with an extension\n             >5cm\u00b2\n\n          -  Vitiligo lasting at least one year at the backs of both hands\n\n          -  Stable vitiligo, defined as vitiligo that presents no evident evolution (appearance\n             of new lesions or increase in the extension of lesions already present) for at least\n             6 months\n\n          -  Suspension for at least two months prior to the enrollment date of any systemic drug\n             for vitiligo such as immunosuppressive treatment (cyclosporine, systemic steroids) or\n             psoralen + ultraviolet A therapy, phototherapy with ultraviolet B, and of any\n             anticoagulant drug\n\n          -  Suspension of topical medications for at least 15 days prior to the enrollment date\n\n        Exclusion Criteria:\n\n          -  Presence of active vitiligo or Koebner phenomenon\n\n          -  Difference of more than 10% in the extension of symmetrical areas of vitiligo\n\n          -  Presence of systemic infections or infections localized to the tissues intended for\n             transplantation\n\n          -  History of infections to the tissues intended for transplantation (herpes simplex,\n             human papillomavirus infections, pityriasis versicolor, pityriasis alba)\n\n          -  Presence or history of malignancy\n\n          -  Chemotherapy or radiation therapy in progress\n\n          -  History of allergies or adverse reactions to local anesthetics\n\n          -  Presence of transmissible diseases (human immunodeficiency virus, hepatitis B and C,\n             human T-lymphotropic virus type I and II, syphilis, cytomegalovirus,\n             Creutzfeldt-Jacob, tuberculosis)\n\n          -  Women who are pregnant or intend to become pregnant during the study period\n             (including breastfeeding women)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01923142", 
            "org_study_id": "VIT-FOL1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Outer-Root-Sheath Melanocytes Suspension", 
                "description": "The treatment consists in depositing a suspension of autologous outer-root-sheath melanocytes, derived from patient's plucked hair follicles, and patient's own serum on the area affected by vitiligo, after properly preparation with dermal needling.", 
                "intervention_name": "Outer-Root-Sheath Melanocytes Suspension", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "The treatment consists in depositing a solution made of saline and patient's own serum on the area affected by vitiligo, after properly preparation with dermal needling.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Vitiligo", 
            "Outer-Root-Sheath", 
            "Melanocytes", 
            "Hair Follicles"
        ], 
        "lastchanged_date": "January 15, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bergamo", 
                        "country": "Italy", 
                        "zip": "24127"
                    }, 
                    "name": "Papa Giovanni XXIII Hospital"
                }, 
                "investigator": {
                    "last_name": "Luigi Naldi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brescia", 
                        "country": "Italy", 
                        "zip": "25123"
                    }, 
                    "name": "Spedali Civili"
                }, 
                "investigator": {
                    "last_name": "Piergiacomo Calzavara Pinton, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Double Blind Within-Subject Controlled Study of Autologous Hair Follicle Outer-Root-Sheath Melanocytes Transplantation in the Treatment of Vitiligo", 
        "overall_contact": {
            "email": "simone.cazzaniga@gised.it", 
            "last_name": "Simone Cazzaniga", 
            "phone": "+39 035 2278 719"
        }, 
        "overall_official": {
            "affiliation": "Centro Studi Gised", 
            "last_name": "Luigi Naldi, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Italy: Ethics Committee", 
                "Italy: National Bioethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Repigmentation equal to or greater than 50% of the treated areas from baseline as assessed by image analysis", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01923142"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Any repigmentation of the treated areas from baseline as assessed by physician according to an ordinal 6-points scale", 
                "safety_issue": "No", 
                "time_frame": "6 weeks, 12 weeks"
            }, 
            {
                "measure": "Any repigmentation of the treated areas from baseline as assessed by patient according to an ordinal 6-points scale", 
                "safety_issue": "No", 
                "time_frame": "6 weeks, 12 weeks"
            }, 
            {
                "measure": "Overall patient satisfaction to the proposed therapy as assessed by visual analogue scale", 
                "safety_issue": "No", 
                "time_frame": "6 weeks, 12 weeks"
            }, 
            {
                "measure": "Any repigmentation of the treated areas from baseline as assessed by image analysis", 
                "safety_issue": "No", 
                "time_frame": "6 weeks, 12 weeks"
            }, 
            {
                "measure": "Any repigmentation of other areas affected by vitiligo from baseline as assessed by physician according to an ordinal 6-points scale (evaluation of a possible systemic effect)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks, 12 weeks"
            }
        ], 
        "source": "Centro Studi Gised", 
        "sponsors": {
            "collaborator": {
                "agency": "ARIV Onlus", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Centro Studi Gised", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}